Patents Represented by Attorney Matthew Mulkeen

Find this attorney in the Justia Lawyer Directory

  • Combination of an HDAC inhibitor and an antimetabolite
    Patent number: 8093220
    Abstract: The invention relates to a combination which comprises: (a) a HDAI; and (b) an anti-metabolite, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases, more specifically MDS or AML. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating MDS or AML, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: January 10, 2012
    Assignee: Novartis AG
    Inventor: Peter Wisdom Atadja
  • Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4?-(trifluoromethoxy)[1,1?-biphenyl]-3-carboxamide
    Patent number: 8063043
    Abstract: Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4?-(trifluoromethoxy)[1,1?-biphenyl]-3-carboxamide are prepared and characterized.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: November 22, 2011
    Assignee: Novartis AG
    Inventors: Joginder Bajwa, Marilyn de la Cruz, Stephanie Kay Dodd, Liladhar Murlidhar Waykole, Raeann Wu
  • Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
    Patent number: 7989494
    Abstract: Polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide free base and salts thereof are prepared by various processes.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: August 2, 2011
    Assignee: Novartis AG
    Inventors: Murat Acemoglu, Joginder S. Bajwa, Piotr Karpinski, Dimitris Papoutsakis, Joel Slade, Frank Stowasser
  • Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
    Patent number: 7989639
    Abstract: Salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide are prepared by various methods.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: August 2, 2011
    Assignee: Novartis AG
    Inventors: Joginder S. Bajwa, David John Parker, Joel Slade
  • Process for the synthesis of organic compounds
    Patent number: 7709657
    Abstract: The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is an intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: May 4, 2010
    Assignee: Novartis AG
    Inventors: Murat Acemoglu, Berthold Schenkel, Wen-Chung Shieh, Song Xue, Erich Widmer, Pedro Garcia Fuentes, Jose Martin Medina, Francisco Vicente Baños
  • Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
    Patent number: 7666874
    Abstract: The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFR?-induced or TEL-PDGFR?-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndrome, chronic eosinophilic leukemia and hypereosinophilic syndrome with resistance to imatinib, or other diseases associated with FIP1L1-PDGFR?, TEL-PDGFR? or similar mutations that activate PDGFR.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: February 23, 2010
    Assignee: Novartis AG
    Inventors: Paul W. Manley, Jürgen Mestan, Doriano Fabbro